GSK (GLAXF) Other Current Liabilities: $3,327 Mil (As of Mar. 2026)


GLAXF GSK PLC GLAXF
75 GF Score
Price $25.33
GF Value $21.09
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Other Current Liabilities?

GSK GLAXF 75 Other Current Liabilities is $3,327 Mil as of Mar. 2026. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.09 (Modestly Overvalued). The stock has 1 warning sign investors should review.

GSK's other current liabilities for the quarter that ended in Mar. 2026 was $3,327 Mil.

GSK's quarterly other current liabilities increased from Sep. 2025 ($3,350 Mil) to Dec. 2025 ($18,618 Mil) but then declined from Dec. 2025 ($18,618 Mil) to Mar. 2026 ($3,327 Mil).

GSK's annual other current liabilities increased from Dec. 2023 ($17,332 Mil) to Dec. 2024 ($18,664 Mil) but then declined from Dec. 2024 ($18,664 Mil) to Dec. 2025 ($18,618 Mil).

GSK Other Current Liabilities Related Terms

GSK Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for GSK's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Other Current Liabilities Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19,317.82 17,177.83 17,331.65 18,663.72 18,618.47

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,000.00 3,971.51 3,350.00 18,618.47 3,326.67
GLAXF
75GF Score
GSK PLC GLAXF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $3,327 Mil mean?
GSK (GLAXF) has a Other Current Liabilities of $3,327 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on GSK.
Is GSK's Other Current Liabilities too high?
GSK's current Other Current Liabilities is $3,327 Mil. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Other Current Liabilities compare to LLY and JNJ?
GSK's Other Current Liabilities of $3,327 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on GSK. GSK's current Other Current Liabilities is $3,327 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.09, compared to a current price of $25.33 — trading 20.1% above its estimated fair value. The current Other Current Liabilities is $3,327 Mil. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For GSK (GLAXF), the current Other Current Liabilities is $3,327 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $25.33 is trading 20.1% above its estimated GF Value™ of $21.09. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • Other Current Liabilities: $3,327 Mil
  • GF Value™: $21.09 vs. price of $25.33 (20.1% above fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score

Get the complete analysis for GLAXF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.33
Price
$21.09
GF Value